Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVAX-1107 and UVAX-1197 HIV vaccine in healthy adults
NCT06905275Phase 1Suspended
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of UVAX-1107 and UVAX-1197 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of local reactogenicity signs and symptoms at 56 weeks, Incidence of systemic reactogenicity signs and symptoms at 56 weeks and 5 more. Started Jul 2025; status: suspended.
02
Drugs
UVAX-1107UVAX-1197
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06905275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905275.